Who
Vojo Vukovic
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Delcath Systems; Chief Medical Officer, Rein Therapeutics; SVP, Chief Medical Officer, Madrigal Pharmaceuticals.
In numbers
- Trades disclosed
- 36
- Buys
- 9
- Sells
- 2
- Bought
- $396K
- Sold
- $26K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Mar 2010
- Last trade
- 17 Feb 2026
- Last filed
- 18 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —56,500 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —28,250 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —56,500 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —28,250 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code M | —42,000 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Code M | $201K42,000 at $4.78 | filing |
| 7 Feb 2025filed 7 Feb 2025 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —113,000 at $0.00 | filing |
| 19 Mar 2024filed 19 Mar 2024 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Code A | $100K26,882 at $3.72 | filing |
| 12 Feb 2024filed 14 Feb 2024 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —100,500 at $0.00 | filing |
| 12 Dec 2023filed 14 Dec 2023 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Bought | $120K40,000 at $3.00 | filing |
| 16 Nov 2023filed 20 Nov 2023 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Bought | $149K60,000 at $2.48 | filing |
| 30 Mar 2022filed 30 Mar 2022 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 22 Mar 2022filed 24 Mar 2022 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 15 Jun 2021filed 17 Jun 2021 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 31 Jan 2020filed 4 Feb 2020 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 16 Aug 2019filed 20 Aug 2019 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K75,000 at $0.59 | filing |
| 15 Apr 2019filed 17 Apr 2019 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 5 Nov 2018filed 6 Nov 2018 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 2 Oct 2015filed 6 Oct 2015 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —132,300 at $0.00 | filing |
| 2 Mar 2015filed 4 Mar 2015 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —173,280 at $0.00 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Delcath Systems, Inc.: Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaDCTH · finanznachrichten.de · 19 Oct 2026Head-To-Head Analysis: Delcath Systems (NASDAQ:DCTH) & Neogen (NASDAQ:NEOG)DCTH · themarketsdaily.com · 18 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Analyzing Green Thumb Industries (OTCMKTS:GTBIF) and Delcath Systems (NASDAQ:DCTH)DCTH · dailypolitical.com · 10 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Vojo Vukovic; 6 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.